CRISPR Therapeutics AG (CRSP)
51.45
+0.69
(+1.36%)
USD |
NASDAQ |
Nov 04, 13:17
CRISPR Therapeutics Enterprise Value: 3.839B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 3.839B |
| October 31, 2024 | 3.466B |
| October 30, 2024 | 3.598B |
| October 29, 2024 | 3.684B |
| October 28, 2024 | 3.749B |
| October 25, 2024 | 3.549B |
| October 24, 2024 | 3.599B |
| October 23, 2024 | 3.433B |
| October 22, 2024 | 3.607B |
| October 21, 2024 | 3.647B |
| October 18, 2024 | 3.682B |
| October 17, 2024 | 3.628B |
| October 16, 2024 | 3.689B |
| October 15, 2024 | 3.608B |
| October 14, 2024 | 3.589B |
| October 11, 2024 | 3.506B |
| October 10, 2024 | 3.381B |
| October 09, 2024 | 3.382B |
| October 08, 2024 | 3.365B |
| October 07, 2024 | 3.390B |
| October 04, 2024 | 3.380B |
| October 03, 2024 | 3.340B |
| October 02, 2024 | 3.409B |
| October 01, 2024 | 3.397B |
| September 30, 2024 | 3.517B |
| Date | Value |
|---|---|
| September 27, 2024 | 3.546B |
| September 26, 2024 | 3.475B |
| September 25, 2024 | 3.426B |
| September 24, 2024 | 3.501B |
| September 23, 2024 | 3.496B |
| September 20, 2024 | 3.619B |
| September 19, 2024 | 3.731B |
| September 18, 2024 | 3.739B |
| September 17, 2024 | 3.763B |
| September 16, 2024 | 3.581B |
| September 13, 2024 | 3.684B |
| September 12, 2024 | 3.424B |
| September 11, 2024 | 3.386B |
| September 10, 2024 | 3.398B |
| September 09, 2024 | 3.337B |
| September 06, 2024 | 3.316B |
| September 05, 2024 | 3.369B |
| September 04, 2024 | 3.351B |
| September 03, 2024 | 3.392B |
| August 30, 2024 | 3.580B |
| August 29, 2024 | 3.565B |
| August 28, 2024 | 3.559B |
| August 27, 2024 | 3.624B |
| August 26, 2024 | 3.703B |
| August 23, 2024 | 3.662B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.107B
Minimum
Mar 16 2020
13.83B
Maximum
Jan 14 2021
3.978B
Average
3.286B
Median
Aug 19 2022
Enterprise Value Benchmarks
| Vertex Pharmaceuticals Inc | 115.80B |
| AC Immune SA | 102.01M |
| Addex Therapeutics Ltd | 7.218M |
| NLS Pharmaceutics Ltd | 14.90M |
| Molecular Partners AG | 26.06M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -126.41M |
| Total Expenses (Quarterly) | 151.26M |
| EPS Diluted (Quarterly) | -1.49 |
| Earnings Yield | -6.22% |
| Normalized Earnings Yield | -3.751 |